Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1316659

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1316659

Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

PUBLISHED:
PAGES: 189 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & Online Access - 1 Year (Single User License)
USD 4749
PDF, Excel & Online Access - 1 Year (Up to 5 User License)
USD 5749
PDF, Excel & Online Access - 1 Year (Site License)
USD 6749
PDF, Excel & Online Access - 1 Year (Enterprise User License)
USD 8749

Add to Cart

The Global Chronic Obstructive Pulmonary Disease Therapeutics Market is forecasted to grow significantly, with a projected USD 20.30 billion in 2023 at a CAGR of 7.36% and expected to reach a staggering USD 33.44 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Chronic Obstructive Pulmonary Disease Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Chronic Obstructive Pulmonary Disease Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Class, market is studied across Bronchodilators, Combination, Corticosteroids, Mucokinetics, and Phosphodiesterase Type 4 Inhibitors. The Combination is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Chronic Obstructive Pulmonary Disease Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Chronic Obstructive Pulmonary Disease Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

6. What is the market share of the leading vendors in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

Product Code: MRR-4311CE1A3395

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Drug Class, 2022 vs 2030
  • 4.3. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel, 2022 vs 2030
  • 4.4. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of chronic obstructive pulmonary disease (COPD) patients worldwide
      • 5.1.1.2. Grwoth in the awareness and early diagnosis of COPD diseases
      • 5.1.1.3. Surge in demand for home care therapeutic devices
    • 5.1.2. Restraints
      • 5.1.2.1. Strict rules and regulations imposed by the government
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing R&D in drug class of COPD drugs
      • 5.1.3.2. Rise in the number of product launches with the regulatory approval
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effect associated with the treatment
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bronchodilators
  • 6.3. Combination
  • 6.4. Corticosteroids
  • 6.5. Mucokinetics
  • 6.6. Phosphodiesterase Type 4 Inhibitors

7. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas Chronic Obstructive Pulmonary Disease Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
Product Code: MRR-4311CE1A3395

LIST OF FIGURES

  • FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
  • FIGURE 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET DYNAMICS
  • FIGURE 8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 101. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 102. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET LICENSE & PRICING
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!